Medical Devices; General Hospital and Personal Use Devices; Classification of the Diabetes Digital Behavioral Therapeutic Device
Key claim: The FDA is classifying the diabetes digital behavioral therapeutic device into class II with special controls to assure safety and effectiveness while reducing regulatory burden and improving patient access.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the diabetes digital behavioral therapeutic device into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the diabetes digital behavioral therapeutic device. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
This classification establishes a defined regulatory pathway for digital behavioral therapeutics targeting diabetes, meaning manufacturers can bring these software-based interventions to market via 510(k) rather than a more burdensome premarket approval process. For patients and providers, it signals FDA recognition of prescription digital therapeutics as a legitimate care modality for chronic disease self-management, potentially expanding access to evidence-based behavioral interventions alongside conventional diabetes treatment.